Genfit S.A. (OTCMKTS:GNFTF) Sees Significant Decline in Short Interest

Genfit S.A. (OTCMKTS:GNFTF) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 18,500 shares, a decrease of 16.7% from the August 15th total of 22,200 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Genfit Price Performance

Genfit stock remained flat at $3.80 during mid-day trading on Tuesday. The stock has a fifty day moving average of $3.80 and a 200 day moving average of $4.05. Genfit has a fifty-two week low of $3.13 and a fifty-two week high of $4.39.

Genfit Company Profile

Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia.